L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination ...
Investing.com -- Tango Therapeutics (NASDAQ:TNGX) stock rose 17% on Thursday after the clinical-stage biotechnology company reported positive data from its ongoing Phase 1/2 study of vopimetostat in ...
Adding immunotherapy to chemotherapy can improve survival in patients with metastatic, poorly differentiated GEP-NECs, data suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback